secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001439725-25-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q2 revenue up 12% to $20M; gross margin 80%; reaffirms FY guidance $80-85M
--------------------------------------------------------------------------------

- Q2 revenue $20.0M (+12% YoY); Lung Diagnostic $17.9M (+8%), Development Services $2.1M (+53%).
- Gross margin 80% (up 150 bps); net loss $11.5M (+6% YoY); Adjusted EBITDA loss $7.2M.
- Reaffirms FY2025 revenue guidance $80-85M; aims for Adjusted EBITDA positive in Q4.
- Sales team expanded to 74 reps (+21% YoY); primary care ordering up >100%; digital ordering up 63%.
- Development services dollars under contract $12.5M (+54% YoY); ALTITUDE trial enrollment complete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000143972525000003/0001439725-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000143972525000003/bdsx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001439725-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer